Stockscreener 앱 받기
3.1152
1.42%
-0.0448
시간 외 거래:
3.12
0.0048
+0.15%
전일 마감가:
$3.16
열려 있는:
$3.1
하루 거래량:
12,066
Relative Volume:
0.30
시가총액:
$16.96M
수익:
-
순이익/손실:
$-16.35M
주가수익비율:
-1.0214
EPS:
-3.05
순현금흐름:
$-11.88M
1주 성능:
-1.73%
1개월 성능:
+8.54%
6개월 성능:
-37.94%
1년 성능:
-61.92%
1일 변동 폭
$3.05
$3.1893
1주일 범위
$3.00
$3.60
52주 변동 폭
$2.6838
$11.79
Lipocine Inc Stock (LPCN) Company Profile
명칭
Lipocine Inc
전화
801 994 7383
주소
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
LPCN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.1152 | 16.96M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-06-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-10 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-11 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | 재개 | H.C. Wainwright | Buy |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
| 2015-06-23 | 개시 | Canaccord Genuity | Buy |
모두보기
Lipocine Inc 주식(LPCN)의 최신 뉴스
HC Wainwright Estimates Lipocine’s Q1 Earnings (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Given Buy Rating at HC Wainwright - Defense World
LPCN Stock Maintains 'Buy' Rating with $8.00 Price Target | LPCN Stock News - GuruFocus
Lipocine partner files for Canadian approval of oral TRT drug By Investing.com - Investing.com South Africa
Verity Pharma Files TLANDO Drug Submission In Canada For Lipocine - Nasdaq
LPCN: Lipocine's TRT Submission in Canada Marks Key Milestone | - GuruFocus
Lipocine Announces Filing Of New Drug Submission For TLANDO In Canada - marketscreener.com
Groundbreaking Oral Testosterone Treatment Eyes 700,000-Strong Canadian Market After FDA Success - Stock Titan
Lipocine’s Partner Files New Drug Submission in Canada - TipRanks
Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
Lipocine Inc. (NASDAQ:LPCN) Short Interest Update - Defense World
Lipocine Approves Key Proposals at Shareholder Meeting - TipRanks
Q2 Earnings Forecast for Lipocine Issued By HC Wainwright - Defense World
HC Wainwright Upgrades Lipocine (NASDAQ:LPCN) to Strong-Buy - Defense World
Lipocine’s (LPCN) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Lipocine (LPCN) Receives Buy Rating from HC Wainwright & Co. | L - GuruFocus
Lipocine (LPCN) Gains Analyst Confidence with Buy Rating and Fut - GuruFocus
Lipocine Gains Bullish New Coverage, With Stock (LPCN) Down 30% YTD - AskTraders.com
Lipocine (LPCN) Gains Analyst Confidence with Buy Rating and Future Prospects | LPCN Stock News - GuruFocus
Lipocine (NASDAQ:LPCN) Share Price Crosses Above Fifty Day Moving Average – Here’s Why - Defense World
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology - Nasdaq
Lipocine’s LPCN 1148 Gains Fast Track Designation - TipRanks
Lipocine (NASDAQ:LPCN) Share Price Passes Below 200 Day Moving Average – Time to Sell? - Defense World
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase - Longview News-Journal
Lipocine to Present at A.G.P. Healthcare Showcase - TipRanks
Lipocine Reveals Next-Gen Oral Drug Delivery Platform at Major Healthcare ConferenceKey Developments Expected - Stock Titan
Lipocine Updates Corporate Presentation for Stakeholders - TipRanks
Lipocine To Present At H.C. Wainwright Annual Neuropsychiatry Virtual Conference - Barchart.com
Lipocine: Q1 Earnings Snapshot - CT Insider
Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 30, 2025 - marketscreener.com
Lipocine Reports Q1 2025 Financial Results - TipRanks
Lipocine Inc. SEC 10-Q Report - TradingView
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 - Morningstar
Renaissance Technologies LLC Sells 4,300 Shares of Lipocine Inc. (NASDAQ:LPCN) - Defense World
Lipocine announces license and supply agreement with Ache - TipRanks
Lipocine Announces License and Supply Agreement for TLANDO® in Brazil - Eagle-Tribune
Lipocine Partners with Aché for TLANDO® in Brazil - TipRanks
LPCN Secures Licensing Deal for TLANDO in Brazil | LPCN Stock Ne - GuruFocus
Lipocine partners with Aché to market TLANDO in Brazil By Investing.com - Investing.com Canada
Lipocine partners with Aché to market TLANDO in Brazil - Investing.com
LPCN Secures Licensing Deal for TLANDO in Brazil | LPCN Stock News - GuruFocus
Lipocine Targets Booming Brazil Testosterone Market with Exclusive TLANDO License Deal as Growth Hits 34% - Stock Titan
Lipocine Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Boosts Holdings in Lipocine Inc. (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com - Defense World
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Lipocine Inc (LPCN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.91%
1.17%
자본화:
|
볼륨(24시간):